What We Do

A New Approach To Cancer Treatment

 

We develop ecDNA-directed therapies (ecDTx) intended to transform the lives of patients with aggressive gene amplified cancers.

Our Pipeline

Our approach is to turn one of cancer’s most enabling mechanisms, extrachromosomal DNA (“ecDNA”), into one of its critical vulnerabilities. Developing a new wave of precision medicines called ecDNA-directed therapies (“ecDTx”), Boundless Bio is committed to improving and extending the lives of patients with oncogene amplified cancers.

It has long been known that high copy number oncogene amplifications facilitate aggressive tumor growth and resistance to cancer treatments, but until recently the mechanism by which oncogene amplified cancers evade therapeutic intervention was not understood. Boundless Bio’s scientific founders and scientists discovered that ecDNA are one of the key culprits and are a differentiated feature of cancer cells that don’t exist in normal cells.

Boundless Bio, with its world leading understanding of ecDNA, is the only company delivering new therapeutic options to patients with oncogene amplified cancers enabled by ecDNA.

What are ecDNA?

 

ecDNA are a primary site for activating oncogene amplifications in cancer. 

ecDNA are large units of circular DNA that reside within the nuclei of cells yet are physically distinct from chromosomal DNA. They often range in size from 1-3 mega base pairs in length and can encode one or more full-length genes and regulatory regions. ecDNA have accessible chromatin and are highly transcribed, meaning they are fully functional and often more active than chromosomally located genes. ecDNA are one of the primary locations for high copy number focal oncogene amplifications in cancer cells; in fact, more than half of all high copy number amplifications in cancer occur on ecDNA.

Spyglass: the only in-class platform built to identify vulnerabilities of ecDNA in cancer

Boundless Bio’s Spyglass platform consists of a comprehensive suite of proprietary ecDNA+/- models across tumor types and oncogene amplifications.  Leveraging innovative molecular analytical technologies and imaging techniques, Spyglass enables characterization of ecDNA in cancer cells and provides a synthetic lethality-based approach to targeting ecDNA-bearing cancers.  Through the use of Spyglass, Boundless Bio scientists have thus far identified and validated four distinct and druggable cellular targets that are essential to the function of ecDNA in cancer cells.

ecDNA are a cancer specific phenomenon

Absent in normal healthy tissue, ecDNA are found in 14% of primary cancers and >40% of metastatic cancers.

Driving high copy number gene amplifications and non-Mendelian genomic adaptation, ecDNA enable tumors to rapidly evolve and switch their oncogene dependency when under therapeutic pressure, thereby rendering current targeted and immunotherapy approaches largely ineffective in patients with gene amplified cancers.

ecDNA are the next frontier of precision medicine

ECHO (ecDNA Harboring Oncogenes) is a proprietary software system for detecting the presence of ecDNA oncogene amplifications using routine clinical next-generation sequencing (NGS).  ECHO is the first portable precision medicine tool for identifying ecDNA amplified oncogenes and built to be deployable at clinical trial sites or commercial laboratories.

In our mission to deliver transformative precision therapies to patients with aggressive oncogene amplified cancers, ECHO is a vital tool in the development of our ground-breaking ecDTx candidates.

The rapidly growing field of ecDNA cancer biology helps explain why some oncogene amplified cancers are so aggressive and why traditional approaches to treatment are not working for many patients. This new understanding of ecDNA shines light onto innovative and differentiated therapeutic approaches to help those affected by the most aggressive tumors. I am thrilled that Boundless Bio has assembled a world class team that has been able to leverage ecDNA biology to develop a host of innovative drug candidates that have the chance to improve the lives of patients with oncogene amplified cancer.

Paul Mischel, M.D.

Scientific Co-Founder and Chairman of the Scientific Advisory Board

P. Mischel

What's New

Take a Look